An official website of the United States government
Here's how you know
Official websites use .mil
A
.mil
website belongs to an official U.S. Department of Defense organization in the United States.
Secure .mil websites use HTTPS
A
lock (
lock
)
or
https://
means you’ve safely connected to the .mil website. Share sensitive information only on official, secure websites.
Skip to main content (Press Enter).
Toggle navigation
JPEO-CBRND
Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense
JPEO-CBRND
Search Joint Program Executive Office for Chemical, Biological Defense (JPEO-CBRND):
Search
Search
Search Joint Program Executive Office for Chemical, Biological Defense (JPEO-CBRND):
Search
Home
Our Story
Leadership
About
Joint Project Managers & Joint Project Leads
Media
News
Photography
Work With Us
JETT - Joint Enterprise Technology Tool
SPARK
Careers
Resources
Coronavirus
Contact
Results:
Archive:
May, 2021
Memorandum of Understanding for Acquisition Support Signed Between the Department of Defense and the Department of Health and Human Services
May 26, 2021
— On May 20, 2021, Deputy Secretary of Defense Kathleen Hicks and Deputy Secretary of Health and Human Services (HHS) Andrea Palm signed a memorandum of understanding (MOU) to continue the agencies’ partnership in defeating COVID-19 and preparing for future public health emergencies.The MOU establishes the framework under which the Department of...
MORE
Interview with Dr. Kevin Wingerd Chief Technology Officer at the Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical)
May 25, 2021
— Excerpt from NCT Magazine's Interview with Dr. Kevin Wingerd, Chief Technology Officer at the Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical)...
MORE
The COVID-19 Pandemic: Acquisition of Diagnostic Equipment and Testing Assays for COVID-19 Lays the Groundwork for Vaccine and Treatment Success
May 25, 2021
— In early 2020, the world as we knew it began to change. Lockdowns, mask mandates, and travel bans became the new normal as the world fought to slow the spread of the coronavirus (COVID-19).Priorities began to shift, and the development of safe and efficacious vaccines and therapeutics for COVID-19, along with the diagnostic capability needed to...
MORE
DOD & HHS Announce DPA Title III Agreement With Retractable Technologies, Inc. to Expand Domestic Production Capacity for Low Dead-Space Safety Syringes and Needles
May 24, 2021
— As part of the national response to COVID-19, the Department of Defense (DOD), in coordination with the Department of Health and Human Services (HHS), signed an agreement with Retractable Technologies, Inc. (RTI) to expand the production of the low dead-space (LDS) safety syringes and needles. Government funding allocated was $27.3 million.LDS...
MORE
Sanofi-GSK report positive interim results for their COVID-19 shot
May 17, 2021
— An experimental COVID-19 vaccine developed by Sanofi and GlaxoSmithKline showed a robust immune response in early-stage clinical trial results, enabling them to move to a late-stage study, the French drugmaker said on Monday...
MORE
JPM CBRN Medical’s RAIDR RF Innovates DOD Medical Acquisition, Wins BRONZE at 2021 Edison Awards
May 14, 2021
— The annual Edison Awards competition is dedicated to honoring excellence and showcasing game-changing innovations that are rapidly reshaping the evolving world around us. An Edison Award recognition is one of the highest accolades an organization can receive, and the Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical...
MORE
Using Ultrasound Stimulation to Reduce Inflammation in COVID-19 In-Patients
May 12, 2021
— Researchers at University of California San Diego School of Medicine have begun a pilot clinical trial to test the efficacy of using ultrasound to stimulate the spleen and reduce COVID-19-related inflammation, decreasing the length of hospital stays...
MORE
INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine
May 10, 2021
— INO-4800 was shown to be safe, well-tolerated and immunogenic in all age groups. Phase 2 results informed INOVIO's selection of 2.0 mg dose for the Phase 3 segment of the trial...
MORE
News Search
News Archive - Search by Year and Month
October 2023 (1)
September 2023 (5)
August 2023 (8)
July 2023 (2)
June 2023 (2)
May 2023 (3)
April 2023 (2)
March 2023 (1)
February 2023 (1)
January 2023 (1)
December 2022 (4)
November 2022 (1)
October 2022 (3)
September 2022 (5)
August 2022 (3)
July 2022 (3)
June 2022 (1)
May 2022 (1)
March 2022 (2)
February 2022 (2)
January 2022 (5)
December 2021 (1)
November 2021 (6)
October 2021 (2)
September 2021 (1)
July 2021 (1)
June 2021 (1)
May 2021 (8)
April 2021 (6)
March 2021 (2)
February 2021 (5)
January 2021 (4)
December 2020 (3)
November 2020 (1)
August 2020 (1)
July 2020 (3)
May 2020 (1)
April 2020 (1)
March 2020 (4)
February 2020 (1)
December 2019 (2)
November 2019 (2)
October 2019 (2)
September 2019 (2)
March 2019 (1)
January 2019 (2)
December 2018 (1)
October 2018 (1)
July 2018 (1)
April 2018 (1)
February 2018 (1)
December 2017 (1)
November 2017 (2)
September 2017 (1)
June 2017 (2)
January 2017 (3)
December 2016 (1)
JPEO-CBRND Press Kit
Download our press kit, which includes helpful documents to better understand our work, such as – Command Brief, Chemical Biological Defense Program's Enterprise strategy, the JPEO-CBRND's Capabilities Catalog, Leadership Biographies, COVID-19 fact sheets, and contracting overview documents.
JPEO-CBRND Public Affairs Office
The JPEO-CBRND Public Affairs Office coordinates and responds to all public affairs and media relations needs on behalf of the JPEO-CBRND. To request a speaker, subject matter expert, or for other interview or request for comment please email our Public Affairs Office email below.